Anemia

Anemia / 2012 / Article / Tab 3

Clinical Study

Safety and Efficacy of Intravenous Ferric Carboxymaltose (750 mg) in the Treatment of Iron Deficiency Anemia: Two Randomized, Controlled Trials

Table 3

Proportion of subjects in the multidose study with a clinically meaningful increase in hemoglobin anytime between baseline and the end of study or time of intervention.

SMC subgroup
FCM Venofer or FerrlecitOral iron Other treatment
(%)

187 (64)59 (57)68 (45)22 (52)
Difference from FCM
95% CI
0.07
(−0.05, 0.18)
0.19
(0.09, 0.29)
0.11
(−0.06, 0.29)
/ (%)

IDA Etiology
 CKD15/34 (44)8/16 (50)2/11 (18)1/4 (25)
 Heavy uterine bleeding55/71 (78)16/25 (64)25/52 (48)8/11 (73)
 IBD/GI related41/61 (67)19/25 (76)4/15 (27)7/15 (47)
 Postpartum16/24 (67)08/18 (44)1/1 (100)
 Other/Unknown60/103 (58)16/37 (43)29/56 (52)5/11 (45)

FCM: ferric carboxymaltose; IDA: iron deficiency anemia; SMC: standard medical care.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.